Construction of tissue microarrays from prostate needle biopsy specimens

British Journal of Cancer

Volumn 93, Issue 4, 2005, Pages 478-482

  Jhavar, S ^a   Corbishley, C M ^b   Dearnaley, D ^c   Fisher, C ^c   Falconer, A ^a   Parker, C ^c   Eeles, R ^a   Cooper, C S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Immunohistochemistry; Needle biopsy; Prostate; Tissue microarray

Indexed keywords

ANALYTIC METHOD; ARTICLE; DISEASE MARKER; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR;

BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 24944439986     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602726     Document Type: Article

References (28)

1. Bastacky S, Cieply K, Sherer C, Dhir R, Epstein JI (2004) Use of interphase fluorescence in situ hybridisation in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Hum Pathol 35: 281-289
2. Battifora H, Mehta P (1990) The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724
3. Bostwick DG (1997) Evaluating prostate needle biopsy: therapeutic and prognostic importance. CA Cancer J Clin 47: 297-319
4. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridisation on tissue microarrays. Cancer Res 59: 803-806
5. Cormier JN, Pollock RE (2004) Soft tissue sarcomas. CA Cancer J Clin 54: 94-109
6. Dearnaley DP, Melia J (1997) Early prostate cancer - to treat or not to treat? Lancet 349: 892-893
7. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826
8. Evans AJ (2003) Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 56: 892-897
9. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS (2004) Transcription factor E2F3 over expressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871-5879
10. Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL, Epstein JI, Hamilton SR, Gannot G, Baibakova GV, Calvert VS, Flaig MJ, Chuaqui RF, Herring JC, Pfeifer J, Petricoin EF, Linehan WM, Duray PH, Bova GS, Emmert-Buck MR (2002) Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 160: 449-457
11. Hoos A, Cordon-Cardo C (2001) Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81: 1331-1338
12. Jereczek-Fossa BA, Jassem J, Orecchia R (2004) Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 30: 153-164
13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 4: 844-847
14. Makin CA, Bobrow LG, Bodmer WF (1984) Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol 37: 975-983
15. Mengel M, Kreipe H, von Wasielewski R (2003) Rapid and large-scale transition of new tumour biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol 11: 261-268
16. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumours and cultured cells. Cell 31: 11-24
17. Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, Harris JR, O'Malley F, Schnitt SJ, Singletary SE, Winchester DP (2002) Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin 52: 277-300
18. Mucci NR, Akdas G, Manely S, Rubin MA (2000) Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 31: 406-414
19. Neville BW, Day TA (2002) Oral cancer and precancerous lesions. CA Cancer J Clin 52: 195-215
20. Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5: 101-106
21. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF (2003) Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumours. Clin Cancer Res 9: 2406-2415
22. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA (2003) Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95: 661-668
23. Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26: 312-319
24. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G (1999) Tissue microarrays for gene amplification surveys in many different tumour types. Clin Cancer Res 5: 1966-1975
25. Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET (2002) Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 4: 30-36
26. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB (1994) Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridisation in needle biopsies. Cancer Res 54: 3574-3579
27. Tricoli JV, Schoenfeldt M, Conley BA (2004) Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10: 3943-3953
28. Yao SL, Lu-Yao G (2002) Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 94: 958-960